The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Suryanarayana Raju Rudraraju & Others
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Suryanarayana Raju Rudraraju and Krishnaveni Rudraraju, belonging to the Non-Promoter Group, have been allotted 29,56,666 equity shares of Astal Laboratories on 14 January 2026 through a Preferential Allotment pursuant to a share swap. Prior to this, they held zero shares in the company. Post-allotment, their combined holding stands at 7.00% of total share/voting capital (6.72% on a diluted basis), with Suryanarayana Raju Rudraraju holding 29,55,833 shares (7.00%) and Krishnaveni Rudraraju holding 833 shares (negligible). The mode of acquisition is preferential allotment via share swap, not an open market purchase, so no cash consideration was involved. Notably, the company's total equity share capital expanded from 1,07,70,000 shares to 4,22,15,632 shares — nearly a 4-fold increase — indicating a much larger capital expansion event of which this allotment is part.
This is a non-cash, share-swap based acquisition by a non-promoter, so it has no direct impact on stock price from market demand. The 7% stake represents a meaningful new shareholder, but the acquirer is not a promoter and is far from the 25% open-offer trigger threshold. Shareholders should note the sharp expansion of share capital, which will lead to EPS dilution for existing holders.